Vertex will be presenting some important data at the upcoming NACFC conference in early October. Combination trials (Kalydeco + lumacaftor) in people with CF who are homozygous for F508del-CFTR. Presentations are expected to include previously announced data as well as new interim data from a Phase 3 rollover study in patients who completed 24 weeks of treatment in either TRAFFIC or TRANSPORT.
Hopefully we will hear some good news!!
Join the discussion on Facebook! https://www.facebook.com/knowcf/posts/10152802348133777
- Chris
Hopefully we will hear some good news!!
Join the discussion on Facebook! https://www.facebook.com/knowcf/posts/10152802348133777
- Chris